Skip to main content
Premium Trial:

Request an Annual Quote

Epigenomics and Biopsytec Cross-License Genetic Technologies

SAN FRANCISCO, April 25 - German biotechs Epigenomics and Biopsytec said on Thursday that they have cross-licensed each other's genetic analysis technologies.

 

Epigenomics has exclusive rights to use Biopsytec's Identification of Linkage Disequilibrium technology in pharmaceutical research and diagnostics. Biopsytec has exclusive rights to use Epigenomics' DNA-methylation technologies in agricultural research.

 

Financial terms of the agreement were not disclosed.

 

Epigenomics said it would apply ILD technology to discovery of new drug targets and the identification of the genetic causes of adverse side-effects in patient populations involved in clinical trials.

 

Biopsytec, an agricultural genetics company, plans to use the DNA-methylation technology to turn on and off genes to improve the results of animal and plant breeding.

 

"With Biopsytec being an agricultural specialist and Epigenomics focusing exclusively on human health care, this agreement is a perfect fit," Arno Heuermann, CEO of Biopsytec, said in a statement. "Each company provides the other with the complementary technologies that enable a comprehensive and unique approach to the two very different markets."

 

Both companies are based in Berlin.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.